Dirk Arnold
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes
Papers in
- Co-authors
- Andrès M.R. Cervantes (23 shared papers)Emmanuel Tiret (2 shared papers)Bernard Nordlinger (3 shared papers)Bengt L. G. Glimelius (1 shared paper)Eric Van Cutsem (15 shared papers)Rob Glynne‐Jones (5 shared papers)Karin M. Haustermans (5 shared papers)David Cunningham (8 shared papers)
In The Last Decade
Dirk Arnold
219 papers receiving 24.9k citations
Dirk Arnold's Hit Papers
Peers
Comparison fields: 5 of 150
- Oncology 14.5k
- Pulmonary and Respiratory Medicine 3.2k
- Hepatology 849
- Surgery 3.5k
- Cancer Research 1.1k
Countries citing papers authored by Dirk Arnold
This map shows the geographic impact of Dirk Arnold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Arnold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Arnold more than expected).
Fields of papers citing papers by Dirk Arnold
This network shows the impact of papers produced by Dirk Arnold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Arnold. The network helps show where Dirk Arnold may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk Arnold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 231 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Hit paper breakdown → | 2016 | 2685 |
| 2 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1560 |
| 3 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1503 |
| 4 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Hit paper breakdown → | 2012 | 1231 |
| 5 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 1223 |
| 6 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1216 |
| 7 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 1143 |
| 8 | Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 1071 |
| 9 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 964 |
| 10 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 959 |
| 11 | Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 856 |
| 12 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials Hit paper breakdown → | 2017 | 655 |
| 13 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2015 | 574 |
| 14 | Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial Hit paper breakdown → | 2012 | 560 |
| 15 | Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 535 |
| 16 | Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 419 |
| 17 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer Hit paper breakdown → | 2017 | 379 |
| 18 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 364 |
| 19 | Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 303 |
| 20 | 2016 | 267 |
About Dirk Arnold
Dirk Arnold is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Neurology and Pathology and Forensic Medicine, having authored 231 papers that have together received 25.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (101 papers), Colorectal Cancer Surgical Treatments (33 papers), Gastric Cancer Management and Outcomes (15 papers), Colorectal and Anal Carcinomas (9 papers), Pancreatic and Hepatic Oncology Research (9 papers), Intraperitoneal and Appendiceal Malignancies (8 papers), Facial Nerve Paralysis Treatment and Research (6 papers) and Esophageal Cancer Research and Treatment (6 papers). The work is most often cited by research in Oncology (14.5k citations), Pulmonary and Respiratory Medicine (3.2k citations), Hepatology (849 citations), Surgery (3.5k citations) and Cancer Research (1.1k citations). Dirk Arnold has collaborated with scholars based in Germany, Spain and France. Frequent co-authors include Andrès M.R. Cervantes, Emmanuel Tiret, Bernard Nordlinger, Bengt L. G. Glimelius, Eric Van Cutsem, Rob Glynne‐Jones, Karin M. Haustermans, David Cunningham, William Allum and Marcel Verheij. Their work appears in journals such as Annals of Oncology, BMC Cancer, ESMO Open, Clinical Colorectal Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.